MILAN–(BUSINESS WIRE)–Dipharma Francis S.r.l., (Dipharma), a leading European manufacturer of
Active Pharmaceutical Ingredients, is pleased to communicate that it has
completed its previously announced acquisition of Kalexsyn, Inc.
(Kalexsyn), a world-class Contract Research Organization (CRO) providing
chemistry services to the biotechnology and pharmaceutical industry.
Pursuant to an agreement dated March 19, 2018, Dipharma has acquired all
of the issued and outstanding shares of Kalexsyn through its American
subsidiary Dipharma, Inc.
Kalexsyn, based in Kalamazoo, Michigan (USA), was founded in 2003 and
provides chemistry services that support the drug discovery and
development activities of their customers.
About Dipharma Francis S.r.l.
With revenues exceeding USD 125 million, Dipharma is one of the leading
family-owned European manufacturers of Active Pharmaceutical
Ingredients. Its three manufacturing sites located in northern Italy
have been successfully inspected by the major health authorities since
1970. The Company develops innovative chemical processes and crystalline
forms for the most renowned pharmaceutical companies in USA, Europe,
Japan, and other regions of the globe. Its manufacturing facilities
supply from laboratory to industrial quantities whilst complying fully
with the most stringent quality standards.
About Kalexsyn, Inc.
Kalexsyn is a world-class chemistry CRO, whose scientists average 15
years’ experience in hit validation, lead optimization and solving tough
synthetic problems. It provides stable label synthesis, custom
synthesis, process impurity synthesis, and process route development to
its world-wide clients. Kalexsyn offers an outstanding CRO experience
with fixed quote as well as short and long-term FTE arrangements. The
Company has research laboratories in Kalamazoo, Michigan.